Literature DB >> 9371628

Enhancement of feline immunodeficiency virus (FIV) infection after DNA vaccination with the FIV envelope.

J Richardson1, A Moraillon, S Baud, A M Cuisinier, P Sonigo, G Pancino.   

Abstract

Despite intensive experimentation to develop effective and safe vaccines against the human immunodeficiency viruses and other pathogenic lentiviruses, it remains unclear whether an immune response that does not afford protection may, on the contrary, produce adverse effects. In the present study, the effect of genetic immunization with the env gene was examined in a natural animal model of lentivirus pathogenesis, infection of cats by the feline immunodeficiency virus (FIV). Three groups of seven cats were immunized by intramuscular transfer of plasmid DNAs expressing either the wild-type envelope or two envelopes bearing mutations in the principal immunodominant domain of the transmembrane glycoprotein. Upon homologous challenge, determination of plasma virus load showed that the acute phase of viral infection occurred earlier in the three groups of cats immunized with FIV envelopes than in the control cats. Genetic immunization, however, elicited low or undetectable levels of antibodies directed against envelope glycoproteins. These results suggest that immunization with the FIV env gene may result in enhancement of infection and that mechanisms unrelated to enhancing antibodies underlay the observed acceleration.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9371628      PMCID: PMC230272     

Source DB:  PubMed          Journal:  J Virol        ISSN: 0022-538X            Impact factor:   5.103


  75 in total

Review 1.  Exposing the immunology of naked DNA vaccines.

Authors:  D M Pardoll; A M Beckerleg
Journal:  Immunity       Date:  1995-08       Impact factor: 31.745

2.  gp 120: good, bad or indifferent?

Authors:  F R Steele
Journal:  Nat Med       Date:  1995-11       Impact factor: 53.440

3.  The HIV glycoprotein gp 160 has superantigen-like properties.

Authors:  P N Akolkar; B Gulwani-Akolkar; N Chirmule; S Pahwa; V S Kalyanaraman; R Pergolizzi; S Macphail; J Silver
Journal:  Clin Immunol Immunopathol       Date:  1995-09

4.  Induction of humoral and cellular immune responses to the human immunodeficiency type 1 virus in nonhuman primates by in vivo DNA inoculation.

Authors:  B Wang; J Boyer; V Srikantan; K Ugen; L Gilbert; C Phan; K Dang; M Merva; M G Agadjanyan; M Newman
Journal:  Virology       Date:  1995-08-01       Impact factor: 3.616

5.  Replicative function and neutralization sensitivity of envelope glycoproteins from primary and T-cell line-passaged human immunodeficiency virus type 1 isolates.

Authors:  N Sullivan; Y Sun; J Li; W Hofmann; J Sodroski
Journal:  J Virol       Date:  1995-07       Impact factor: 5.103

6.  Human immunodeficiency virus 1 reservoir in CD4+ T cells is restricted to certain V beta subsets.

Authors:  D Dobrescu; S Kabak; K Mehta; C H Suh; A Asch; P U Cameron; A S Hodtsev; D N Posnett
Journal:  Proc Natl Acad Sci U S A       Date:  1995-06-06       Impact factor: 11.205

7.  Human immunodeficiency virus-type 1 replication can be increased in peripheral blood of seropositive patients after influenza vaccination.

Authors:  W A O'Brien; K Grovit-Ferbas; A Namazi; S Ovcak-Derzic; H J Wang; J Park; C Yeramian; S H Mao; J A Zack
Journal:  Blood       Date:  1995-08-01       Impact factor: 22.113

8.  Induction of potent humoral and cell-mediated immune responses following direct injection of DNA encoding the HIV type 1 env and rev gene products.

Authors:  K Okuda; H Bukawa; K Hamajima; S Kawamoto; K Sekigawa; Y Yamada; S Tanaka; N Ishi; I Aoki; M Nakamura
Journal:  AIDS Res Hum Retroviruses       Date:  1995-08       Impact factor: 2.205

9.  Use of DNAs expressing HIV-1 Env and noninfectious HIV-1 particles to raise antibody responses in mice.

Authors:  S Lu; J C Santoro; D H Fuller; J R Haynes; H L Robinson
Journal:  Virology       Date:  1995-05-10       Impact factor: 3.616

10.  Enhancement of feline immunodeficiency virus infection after immunization with envelope glycoprotein subunit vaccines.

Authors:  K H Siebelink; E Tijhaar; R C Huisman; W Huisman; A de Ronde; I H Darby; M J Francis; G F Rimmelzwaan; A D Osterhaus
Journal:  J Virol       Date:  1995-06       Impact factor: 5.103

View more
  21 in total

1.  AIDS vaccination studies with an ex vivo feline immunodeficiency virus model: analysis of the accessory ORF-A protein and DNA as protective immunogens.

Authors:  Mauro Pistello; Francesca Bonci; J Norman Flynn; Paola Mazzetti; Patrizia Isola; Elisa Zabogli; Valentina Camerini; Donatella Matteucci; Giulia Freer; Paolo Pelosi; Mauro Bendinelli
Journal:  J Virol       Date:  2006-09       Impact factor: 5.103

2.  Conserved epitopes on HIV-1, FIV and SIV p24 proteins are recognized by HIV-1 infected subjects.

Authors:  Shannon R Roff; Missa P Sanou; Mobeen H Rathore; Jay A Levy; Janet K Yamamoto
Journal:  Hum Vaccin Immunother       Date:  2015       Impact factor: 3.452

3.  Feline leukemia virus DNA vaccine efficacy is enhanced by coadministration with interleukin-12 (IL-12) and IL-18 expression vectors.

Authors:  L Hanlon; D Argyle; D Bain; L Nicolson; S Dunham; M C Golder; M McDonald; C McGillivray; O Jarrett; J C Neil; D E Onions
Journal:  J Virol       Date:  2001-09       Impact factor: 5.103

Review 4.  Vaccine development against HIV-1: current perspectives and future directions.

Authors:  Rebecca L Edgeworth; Juan Homero San; Jason A Rosenzweig; Nang L Nguyen; Jean D Boyer; Kenneth E Ugen
Journal:  Immunol Res       Date:  2002       Impact factor: 2.829

5.  Immunogenicity of an anti-clade B feline immunodeficiency fixed-cell virus vaccine in field cats.

Authors:  D Matteucci; A Poli; P Mazzetti; S Sozzi; F Bonci; P Isola; L Zaccaro; S Giannecchini; M Calandrella; M Pistello; S Specter; M Bendinelli
Journal:  J Virol       Date:  2000-12       Impact factor: 5.103

6.  Enhanced SIV replication and accelerated progression to AIDS in macaques primed to mount a CD4 T cell response to the SIV envelope protein.

Authors:  Silvija I Staprans; Ashley P Barry; Guido Silvestri; Jeffrey T Safrit; Natalia Kozyr; Beth Sumpter; Hanh Nguyen; Harold McClure; David Montefiori; Jeffrey I Cohen; Mark B Feinberg
Journal:  Proc Natl Acad Sci U S A       Date:  2004-08-23       Impact factor: 11.205

7.  Association of plasma viral RNA load with prognosis in cats naturally infected with feline immunodeficiency virus.

Authors:  Yuko Goto; Yoshiaki Nishimura; Kenji Baba; Takuya Mizuno; Yasuyuki Endo; Kenichi Masuda; Koichi Ohno; Hajime Tsujimoto
Journal:  J Virol       Date:  2002-10       Impact factor: 5.103

8.  Kinetics of replication of a partially attenuated virus and of the challenge virus during a three-year intersubtype feline immunodeficiency virus superinfection experiment in cats.

Authors:  M Pistello; D Matteucci; G Cammarota; P Mazzetti; S Giannecchini; D Del Mauro; S Macchi; L Zaccaro; M Bendinelli
Journal:  J Virol       Date:  1999-02       Impact factor: 5.103

9.  Antibodies generated in cats by a lipopeptide reproducing the membrane-proximal external region of the feline immunodeficiency virus transmembrane enhance virus infectivity.

Authors:  Simone Giannecchini; Anna Maria D'Ursi; Cinzia Esposito; Mario Scrima; Elisa Zabogli; Giulia Freer; Paolo Rovero; Mauro Bendinelli
Journal:  Clin Vaccine Immunol       Date:  2007-06-27

10.  DNA vaccination affords significant protection against feline immunodeficiency virus infection without inducing detectable antiviral antibodies.

Authors:  M J Hosie; J N Flynn; M A Rigby; C Cannon; T Dunsford; N A Mackay; D Argyle; B J Willett; T Miyazawa; D E Onions; O Jarrett; J C Neil
Journal:  J Virol       Date:  1998-09       Impact factor: 5.103

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.